May 15, 2020
Lipocine Announces Presentations on TLANDO(TM) at AUA Virtual Experience 2020
May 13, 2020
Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model
May 05, 2020
FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial
Apr 17, 2020
U.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition
Feb 11, 2020
Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics
Nov 11, 2019
Lipocine Receives Complete Response Letter for TLANDO(TM) from U.S. FDA
Oct 10, 2019
Lipocine to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference
Oct 01, 2019
Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019
Sep 30, 2019
First Biopsy Confirmed Nash Patient Dosed In Lipocine LiFT Study Of LPCN 1144
Sep 23, 2019
Lipocine Announces Presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America
Sep 17, 2019
Lipocine to Present at the Ladenburg Thalmann 2019 Healthcare Conference
Aug 27, 2019
Lipocine Announces Trial Date in Lipocine's Infringement Lawsuit Against Clarus Therapeutics and Will Seek a Permanent Injunction
Jul 23, 2019
Lipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population
Jun 27, 2019
Hypogonadism Market Spotlight 2019 - Clinical Trial Activity is Dominated by Completed Trials, and AbbVie Leads with 8 Completed Trials
Mar 14, 2019
Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019
Oct 11, 2018
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018